Coadministration of cruzipain and GM-CSF DNAs, a new immunotherapeutic vaccine against Trypanosoma cruzi infection

References

• Gascon J, Bern C, Pinazo MJ. Chagas disease in Spain, the United States and other non-endemic countries. Acta Trop 2010; 115:22-7; PMID:19646412; http://dx.doi.org/10.1016/j.actatropica.2009.07.019
   PubMed Web of Science ®Google Scholar
• Basile L, Jansà JM, Carlier Y, Salamanca DD, Angheben A, Bartoloni A, Seixas J, Van Gool T, Canavate C, Flores-Chavez M, et al. Chagas disease in European countries: the challenge of a surveillance system. 1–10. Euro Surveill 2011; 16(37):pii=19968; PMID:21944556
   PubMedGoogle Scholar
• Pan American Health Organization, 2012. Enfermedad de Chagas (Trypanosomiasis Americana). Available at: http://new.paho.org/hq/index.php?option=com_content&view=category&layout=blog&id=3591&Itemid=3921&lang=es. Accessed March 1, 2015.
   Google Scholar
• Kirchhoff LV. Epidemiology of American trypanosomiasis (Chagas disease). Adv Parasitol 2011; 75:1-18; PMID:21820549; http://dx.doi.org/10.1016/B978-0-12-385863-4.00001-0
   PubMed Web of Science ®Google Scholar
• Wilkinson SR, Kelly JM. Trypanocidal drugs: mechanisms, resistance and new targets. Expert Rev Mol Med 2009; Oct 29; 11:e31; PMID:19863838; http://dx.doi.org/10.1017/S1462399409001252
   PubMed Web of Science ®Google Scholar
• Garcia S, Ramos CO, Senra JF, Vilas-Boas F, Rodrigues MM, Campos-de-Carvalho AC, Ribeiro-Dos-Santos R, Soares MB. Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations. Antimicrob Agents Chemother 2005 Apr; 49(4):1521-8; PMID:15793134; http://dx.doi.org/10.1128/AAC.49.4.1521-1528.2005
   PubMed Web of Science ®Google Scholar
• Marin-Neto JA, Rassi A, Morillo CA, Avezum A, Connolly SJ, Sosa-Estani S, Rosas F, Yusuf S; BENEFIT Investigators. Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the Benznidazole evaluation for interrupting trypanosomiasis (BENEFIT). Am Heart J 2008; 156(1):37-43; PMID:18585495; http://dx.doi.org/10.1016/j.ahj.2008.04.001
   PubMed Web of Science ®Google Scholar
• Urbina JA. Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches. Acta Trop 2010; 115(1–2):55-68; PMID:19900395; http://dx.doi.org/10.1016/j.actatropica.2009.10.023
   PubMed Web of Science ®Google Scholar
• Castro J a, de Mecca MM, Bartel LC. Toxic side effects of drugs used to treat Chagas' disease (American trypanosomiasis). Hum Exp Toxicol 2006; 25(8):471-9; PMID:16937919; http://dx.doi.org/10.1191/0960327106het653oa
   PubMed Web of Science ®Google Scholar
• Parussini F, Duschak VG, Cazzulo JJ. Membrane-bound cysteine proteinase isoforms in different developmental stages of Trypanosoma cruzi. Cell Mol Biol (Noisy-le-grand) 1998 May; 44(3):513-9; PMID:9620448
   PubMed Web of Science ®Google Scholar
• Berasain P, Carmona C, Frangione B, Cazzulo JJ, Goñi F. Specific cleavage sites on human IgG subclasses by cruzipain, the major cysteine proteinase from Trypanosoma cruzi. Mol Biochem Parasitol 2003; 130(1):23-9; PMID:14550893; http://dx.doi.org/10.1016/S0166-6851(03)00139-7
   PubMed Web of Science ®Google Scholar
• Souto-padron T, Campetella OE, Cazzulo JJ. Cysteine proteinase in Trypanosoma cruzi: immunocytochemical localization and involvement in parasite-host cell interaction. J Cell Sci 1990 Jul; 96 (Pt 3):485-90; PMID:2229199
   PubMed Web of Science ®Google Scholar
• Malchiodi EL, Chiaramonte MG, Taranto NJ, Zwirner NW, Margni RA. Cross-reactivity studies and differential serodiagnosis of human infections caused by Trypanosoma cruzi and Leishmania spp; use of immunoblotting and ELISA with a purified antigen (Ag163B6). Clin Exp Immunol 1994; Sep; 97(3):417-23; PMID:8082296; http://dx.doi.org/10.1111/j.1365-2249.1994.tb06104.x
   PubMed Web of Science ®Google Scholar
• Fissolo N, Montalban X, Comabella M. DNA vaccination techniques. In: Weissert R, ed. Multiple Sclerosis: New York: Springer, 2016:39–50.
   Google Scholar
• Peng S, Song L, Knoff J, Wang JW, Chang YN, Hannaman D, Wu TC, Alvarez RD, Roden RB, Hung CF. Control of HPV-associated tumors by innovative therapeutic HPV DNA vaccine in the absence of CD4+ T cells. Cell Biosci 2014 Mar 4; 4(1):11; PMID:24594273; http://dx.doi.org/10.1186/2045-3701-4-11
   PubMed Web of Science ®Google Scholar
• Diniz MO, Cariri FA, Aps LR and Ferreira LC. Enhanced therapeutic effects conferred by an experimental DNA vaccine targeting human papillomavirus-induced tumors. Hum Gene Ther 2013 Oct; 24(10):861-70; PMID:24007495; http://dx.doi.org/10.1089/hum.2013.102
   PubMed Web of Science ®Google Scholar
• Godon O, Fontaine H, Kahi S, Meritet J, Scott-Algara D, Pol S, Michel M, Bourgine M. Immunological and antiviral responses after therapeutic DNA immunization in chronic hepatitis B patients efficiently treated by analogues. Mol Ther 2014 Mar; 22(3):675-84; PMID:24394187; http://dx.doi.org/10.1038/mt.2013.274
   PubMed Web of Science ®Google Scholar
• Wilson CC, Newman MJ, Livingston BD, MaWhinney S, Forster JE, Scott J, Schooley RT, Benson CA. Clinical phase 1 testing of the safety and immunogenicity of an epitope-based DNA vaccine in human immunodeficiency virus type 1-infected subjects receiving highly active antiretroviral therapy. Clin Vaccine Immunol 2008 Jun; 15(6):986-94; PMID:18400976; http://dx.doi.org/10.1128/CVI.00492-07
   PubMed Web of Science ®Google Scholar
• Palma P, Romiti ML, Montesano C, Santilli V, Mora N, Aquilani A, Dispinseri S, Tchidjou HK, Montano M, Eriksson LE, et al. Therapeutic DNA vaccination of vertically HIV-infected children: report of the first pediatric randomised trial (PEDVAC). PLoS One 2013; 8(11):e79957; PMID:24312194; http://dx.doi.org/10.1371/journal.pone.0079957
   PubMed Web of Science ®Google Scholar
• Zur Megede J, Sanders-Beer B, Silvera P, Golightly D, Bowlsbey A, Hebblewaite D, Sites D, Nieves-Duran L, Srivastava R, Otten GR, et al. A therapeutic SIV DNA vaccine elicits T-cell immune responses, but no sustained control of viremia in SIVmac239-infected rhesus macaques. AIDS Res Hum Retroviruses 2008 Aug; 24(8):1103-16; PMID:18620495; http://dx.doi.org/10.1089/aid.2008.0055
   PubMed Web of Science ®Google Scholar
• Skinner AM, Buddle BM, Wedlock DN, Keen D, de Lisle GW, Tascon RE, Ferraz JC, Lowrie DB, Cockle PJ, Vordermeier HM, et al. A DNA Prime-Mycobacterium bovis BCG boost vaccination strategy for cattle induces protection against bovine tuberculosis. Infect Immun 2003 Sep; 71(9):4901-7; PMID:12933831; http://dx.doi.org/10.1128/IAI.71.9.4901-4907.2003
   PubMed Web of Science ®Google Scholar
• Maroof A, Brown N, Smith B, Hodgkinson MR, Maxwell A, Losch FO, Fritz U, Walden P, Lacey CN, Smith DF, et al. Therapeutic vaccination with recombinant adenovirus reduces splenic parasite burden in experimental visceral leishmaniasis. J Infect Dis 2012 Mar 1; 205(5):853-63; PMID:22301630; http://dx.doi.org/10.1093/infdis/jir842
   PubMed Web of Science ®Google Scholar
• Handman E, Noormohammadi AH, Curtis JM, Baldwin T, Sjölander A. Therapy of murine cutaneous leishmaniasis by DNA vaccination. Vaccine 2000; 18(26):3011-7; PMID:10825604; http://dx.doi.org/10.1016/S0264-410X(00)00109-2
   PubMed Web of Science ®Google Scholar
• Dupré  , Herv M, Schacht AM, Capron A, Riveau G. Control of schistosomiasis pathology by combination of Sm28GST DNA immunization and praziquantel treatment. J Infect Dis 1999 Aug; 180(2):454-63; PMID:10395862; http://dx.doi.org/10.1086/314875
   PubMed Web of Science ®Google Scholar
• Dumonteil E, Escobedo-ortegon J, Reyes-rodriguez N, Arjona-Torres A, Ramirez-Sierra MJ. Immunotherapy of Trypanosoma cruzi infection with DNA vaccines in mice. Infect Immun 2004 Jan; 72(1):46-53; PMID:14688079; http://dx.doi.org/10.1128/IAI.72.1.46-53.2004
   PubMed Web of Science ®Google Scholar
• Quijano-Hernández I, Castro-Barcena A, Vázquez-Chagoyán JC, Bolio-González ME, Ortega-López J, Dumonteil E. Preventive and therapeutic DNA vaccination partially protect dogs against an infectious challenge with Trypanosoma cruzi. Vaccine 2013 Apr 26; 31(18):2246-52; PMID:23499599; http://dx.doi.org/10.1016/j.vaccine.2013.03.005
   PubMed Web of Science ®Google Scholar
• Cazorla SI, Becker PD, Frank FM, Ebensen T, Sartori MJ, Corral RS, Malchiodi EL, Guzmán CA. Oral vaccination with Salmonella enterica as a cruzipain-DNA delivery system confers protective immunity against Trypanosoma cruzi. Infect Immun 2008 Jan; 76(1):324-33; PMID:17967857; http://dx.doi.org/10.1128/IAI.01163-07
   PubMed Web of Science ®Google Scholar
• Cazorla SI, Matos MN, Cerny N, Ramirez C, Alberti AS, Bivona AE, Morales C, Guzmán CA, Malchiodi EL. Oral multicomponent DNA vaccine delivered by attenuated Salmonella elicited immunoprotection against American trypanosomiasis. J Inf Dis 2015; 211(5):698-707; PMID:25160983; http://dx.doi.org/10.1093/infdis/jiu480
   PubMed Web of Science ®Google Scholar
• Chiari E, Camargo EP. Culturing and cloning of Trypanosoma cruzi. In: Morel CM, editor. Genes and antigens of parasites. Rio de Janeiro: Fundacao Oswaldo Cruz; 1984. p. 23-6
   Google Scholar
• Braka K, Doyleb PS, McKerrowb JH, Ellman JA. Identification of a new class of nonpeptidic inhibitors of cruzain. J Am Chem Soc 2008 May 21; 130(20):6404-10; PMID:18435536; http://dx.doi.org/10.1021/ja710254m
   PubMed Web of Science ®Google Scholar
• Chen YT, Liraa R, Hansell E, McKerrow JH, Roush WR. Synthesis of macrocyclic trypanosomal cysteine protease inhibitors. Bioorg Med Chem Lett 2008 November 15; 18(22):5860-3; PMID:18585034; http://dx.doi.org/10.1016/j.bmcl.2008.06.012
   PubMed Web of Science ®Google Scholar
• Bellera CL, Balcazar E, Alberca L, Labriola CA, Talevi A, Carrillo C. Application of computer-aided drug repurposing in the search of new cruzipain inhibitors: discovery of amiodarone and bromocriptine inhibitory effects. J Chem Inf Model 2013 Sep 23; 53(9):2402-8; PMID:23906322; http://dx.doi.org/10.1021/ci400284v
   PubMed Web of Science ®Google Scholar
• Ndao M, Beaulieu C, Black WC, Isabel E, Vasquez-Camargo F, Nath-Chowdhury M, Massé F, Mellon C, Methot N, Nicoll-Griffith DA. Reversible cysteine protease inhibitors show promise for a Chagas disease cure. Antimicrob Agents Chemother 2014 Feb; 58(2):1167-78; PMID:24323474; http://dx.doi.org/10.1128/AAC.01855-13
   PubMed Web of Science ®Google Scholar
• Frank FM, Petray PB, Cazorla SI, Muñoz MC, Corral RS, Malchiodi EL. Use of a purified Trypanosoma cruzi antigen and CpG oligodeoxynucleotides for immunoprotection against a lethal challenge with trypomastigotes. Vaccine 2003; 22(1):77-86; PMID:14604574; http://dx.doi.org/10.1016/S0264-410X(03)00541-3
   PubMed Web of Science ®Google Scholar
• Cazorla SI, Frank FM, Becker PD, Corral RS, Guzmán CA, Malchiodi EL. Prime-boost immunization with cruzipain co-administered with MALP-2 triggers a protective immune response able to decrease parasite burden and tissue injury in an experimental Trypanosoma cruzi infection model. J Infect Dis 2010 Jul 1; 202(1):136-44; PMID:20497050; http://dx.doi.org/10.1086/652872
   PubMed Web of Science ®Google Scholar
• Cazorla SI, Frank FM, Becker PD, Arnaiz M, Mirkin GA, Corral RS, Guzmán CA, Malchiodi EL. Redirection of the immune response to the functional catalitic domain of the cystein proteinasa cruzipain improves protective immunity against Trypanosoma cruzi infection. J Infect Dis 2010 Jul 1; 202(1):136-44; PMID:20497050; http://dx.doi.org/10.1086/652872
   PubMed Web of Science ®Google Scholar
• Schnapp AR, Eickhoff CS, Sizemore D, Curtiss R 3rd, Hoft DF. Cruzipain induces both mucosal and systemic protection against Trypanosoma cruzi in mice. Infect Immun 2002 Sep; 70(9):5065-74
   PubMed Web of Science ®Google Scholar
• Matos MN, Cazorla SI, Bivona AE, Morales C, Guzmán CA, Malchiodi EL. Tc52 amino-terminal-domain DNA carried by attenuated Salmonella enterica serovar Typhimurium induces protection against a Trypanosoma cruzi lethal challenge. Infect Immun 2014 Oct; 82(10):4265-75; PMID:25069980; http://dx.doi.org/10.1128/IAI.02190-14
   PubMed Web of Science ®Google Scholar
• Chianese-Bullock K, Pressley J, Garbee C, Hibbitts S, Murphy C, Yamshchikov G, Petroni GR, Bissonette EA, Neese PY, Grosh WW, et al. MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma. J Immunol 2005 Mar 1; 174(5):3080-6; PMID:15728523; http://dx.doi.org/10.4049/jimmunol.174.5.3080
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Ruby CE, Hughes T, Slingluff CL. Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma. J Immunother Cancer 2014; 2:11; PMID:24971166; http://dx.doi.org/10.1186/2051-1426-2-11
   PubMedGoogle Scholar
• Machado AV, Cardoso JE, Claser C, Rodrigues MM, Gazzinelli RT, Bruna-Romero O. Long-term protective immunity induced against Trypanosoma cruzi infection after vaccination with recombinant adenoviruses encoding amastigote surface protein-2 and trans-sialidase. Hum Gene Ther 2006 Sep; 17(9):898-908; PMID:16972758; http://dx.doi.org/10.1089/hum.2006.17.898
   PubMed Web of Science ®Google Scholar
• Frank FM, Cazorla SI, Sartori MJ, Corral RS. Elicitation of specific, Th1-biased immune response precludes skeletal muscle damage in cruzipain-vaccinated mice. Exp Mol Pathol 2008 Feb; 84(1):64-70; PMID:18054912; http://dx.doi.org/10.1016/j.yexmp.2007.10.004
   PubMed Web of Science ®Google Scholar
• Sullivan NL, Eickhoff CS, Sagartz J, Hoft DF. Deficiency of antigen-specific B cells results in decreased Trypanosoma cruzi systemic but not mucosal immunity due to CD8 T cell exhaustion. J Immunol 2015 Feb 15; 194(4):1806-18; PMID:25595788; http://dx.doi.org/10.4049/jimmunol.1303163
   PubMed Web of Science ®Google Scholar
• Pereira IR, Vilar-Pereira G, Marques V, da Silva AA, Caetano B, Moreira OC, Machado AV, Bruna-Romero O, Rodrigues MM, Gazzinelli RT, et al. A human type 5 adenovirus-based Trypanosoma cruzi therapeutic vaccine re-programs immune response and reverses chronic cardiomyopathy. PLoS Pathog 2015 Jan 24; 11(1):e1004594; PMID:25617628; http://dx.doi.org/10.1371/journal.ppat.1004594
   PubMed Web of Science ®Google Scholar
• Espuelas S, Plano D, Nguewa P, Font M, Palop JA, Irache JM, Sanmartín C. Innovative lead compounds and formulation strategies as newer kinetoplastid therapies. Curr Med Chem 2012; 19(25):4259-88; PMID:22834813; http://dx.doi.org/10.2174/092986712802884222
   PubMed Web of Science ®Google Scholar
• González MN, Dey N, Garg NJ, Postan M. G ranulocyte colony-stimulating factor partially repairs the damage provoked by Trypanosoma cruzi in murine myocardium. Int J Cardiol 2013 Oct 3; 168(3):2567-74; PMID:23597573; http://dx.doi.org/10.1016/j.ijcard.2013.03.049
   PubMed Web of Science ®Google Scholar